High-Purity Metabolic Enzyme Reagents for Purine Biosynthesis Inhibitor Development. Sequence-Verified ADSS2 Proteins, Lentiviral Systems, and Screening-Grade Assay Controls.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADSS2 (Adenylosuccinate Synthase 2) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | ADSS2 Full-Length Recombinant Protein (WT & Mutant Panel) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. |
View ADSS2 Products |
| Mutant Panel | ADSS2 Catalytic Site Mutants (D302N, H336A) Inactive controls for mechanistic studies and resistance mutation profiling. |
View ADSS2 Products |
| Gene Delivery | ADSS2 Premade Lentivirus Particles / Promise-ORF Full-length ORF for stable overexpression in cancer cell lines. HEK293T packaged, titer >1×10⁸ TU/mL. |
View ADSS2 Products |
| Benchmark Ab | Anti-ADSS2 Antibody (Research Grade) Recombinant rabbit monoclonal, sequence verified for WB/IP/Target Engagement. |
View ADSS2 Products |
| Validator | ADSS2 siRNA Set (3 unique sequences) For knockdown validation, specificity confirmation, and synthetic lethality screening. |
View ADSS2 Products |
| Related Target: ADSL | Adenylosuccinate Lyase Downstream pathway enzyme; synthetic lethal partner for combination studies. |
View ADSL Products |
| Related Target: ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase Bifunctional enzyme in purine biosynthesis; essential for pathway counter-screening. |
View ATIC Products |
| Related Target: IMPDH2 | Inosine Monophosphate Dehydrogenase 2 Branch-point enzyme (GMP synthesis); metabolic flux analysis control. |
View IMPDH2 Products |
| Related Target: ADSS1 | Adenylosuccinate Synthase 1 (muscle-specific isoform) Critical for isoform selectivity counter-screening to avoid muscle toxicity. |
View ADSS1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity Coupling (Fumarate detection sensitivity) | High-purity (>95%) active enzyme with confirmed theoretical MW; suitable for coupled spectrophotometric assays (NADH oxidation at 340nm). |
| Isoform Selectivity (ADSS2 vs ADSSL1 vs ADSS1) | Human ADSS2, ADSSL1, and ADSS1 ortholog proteins available separately; sequence-verified distinct constructs for rigorous counter-screening. |
| Cellular Metabolite Interference | Validated siRNA included for target-specificity verification in complex metabolite backgrounds. |
| Resistance Mutation Profiling | Catalytic mutant panel (D302N, H336A) available for mechanistic validation and compound specificity testing. |
Live ADSS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADSS2-targeted therapeutics is intensifying within the metabolic oncology space. As cancers reliant on de novo purine biosynthesis (e.g., hepatocellular carcinoma, breast cancer, certain leukemias) develop resistance to standard therapies, ADSS2 emerges as a critical vulnerability. Early antimetabolites faced toxicity issues, but the next wave shifts toward highly selective allosteric small molecule inhibitors, PROTAC degraders, and synthetic lethal combinations (e.g., ADSS2 + IMPDH blockade) to overcome metabolic compensation. High-fidelity biochemical and cell-based assays remain the primary bottleneck for advancing lead compounds.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia, Emerging biotech | Solid Tumors (purine auxotrophic) | Enzyme Activity Assay (High-purity recombinant protein with confirmed specific activity). |
| PROTAC Degrader | Targeted protein degradation biotechs | Hematologic Malignancies, Refractory Cancers | Cell-Based Validation (Lentivirus overexpression lines for ternary complex formation). |
| siRNA / ASO | RNA therapeutic developers | Metabolic Disorders | Knockdown Validation (Validated siRNA controls for transfection efficiency standardization). |
| Combination (ADSS2 + IMPDH) | Oncology-focused biotechs | Refractory Cancers | Pathway Panel Screening (ADSS2, ADSL, ATIC, IMPDH2 protein set for selectivity profiling). |
| CRISPR / Synthetic Lethality | Functional Genomics Consortia | Solid Tumors, Hematologic Malignancies | Lentivirus ORF and validated siRNA for stable overexpression and knockdown in cancer cell lines. |